Back to Directory
Romiplostim
Performance & EnduranceThrombopoietin receptor agonist for chronic ITP, increases platelet production.
Key Benefits
- ✓Increases platelet count
- ✓Treats chronic ITP
- ✓Reduces bleeding risk
- ✓Alternative to splenectomy
- ✓Long-acting effects
Dosing Information
Dosage Range
1-10 mcg/kg
Frequency
Once weekly
Typical Duration
Ongoing
Detailed Protocol
Administered via subcutaneous injection once weekly. Dose adjusted based on platelet counts. Requires medical supervision and regular monitoring.
About Romiplostim
Romiplostim (Nplate) is a peptibody (peptide-Fc fusion) that activates the thrombopoietin receptor, stimulating platelet production. FDA-approved for chronic immune thrombocytopenia (ITP) in patients with insufficient response to other treatments.
Research Notes
FDA-approved in 2008 for chronic ITP. Clinical studies show sustained platelet count increases. Requires REMS program and regular monitoring.
Potential Side Effects
- •Headache
- •Arthralgia
- •Dizziness
- •Thrombosis risk
- •Bone marrow fibrosis risk
- •Requires monitoring
Always consult with a healthcare professional before starting any peptide therapy.